A519V

Category 3/4 — Most DruggableUncertain significanceTransmembrane · predictedSource card

Alanine → Valine at position 519 · Cytoplasmic loop 4 · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference

Wild-type A519 — hydrogen bond to F515

Fullscreen ↗

DynaMut2 mutant · A519V

Mutant V519 — van der waals contact to L521 lost

Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

1 lost2 gained10 preserved

Interaction type	Wild-type partner	Mutant partner	Status
Hydrogen bond	F515	F515	Preserved
Hydrogen bond	F516	F516	Preserved
Hydrogen bond	F524	F524	Preserved
Polar contact	F515	F515	Preserved
Polar contact	F516	F516	Preserved
Polar contact	L521	L521	Preserved
Polar contact	F524	F524	Preserved
Van der Waals	—	F516	Gained
Van der Waals	R517	R517	Preserved
Van der Waals	L521	—	Lost
Hydrophobic	—	F524	Gained
Hydrophobic	T527	T527	Preserved
Hydrophobic	L531	L531	Preserved

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG

-1.03kcal/mol

Destabilising — moderate

AlphaMissense

0.713

likely pathogenic

AlphaFold pLDDT

model confidence

Schema

Cat 3/4

Category 3/4 — Most Druggable

Clinical Evidence

ClinVar classificationUncertain significance

Review statuscriteria provided, multiple submitters, no conflicts

Associated conditionsAutosomal dominant nonsyndromic hearing loss 6; Type 2 diabetes mellitus; Wolfram syndrome 1; Cataract 41; Wolfram-like syndrome

Population frequency (gnomAD v4)Ultra-rare · AF 0.00062%

cDNA changec.1556C>T

ClinVar accessionVCV000166592

Last evaluated2025/06/22 00:00

Observed at very low frequency in gnomAD.

Full Variant Card

WFS1 Wolframin — A519V Variant Card

Molecular Atlas Pilot · RareResearch.AI · Generated by wolfram-variant-card skill

Alanine → Valine at position 519. Cytoplasmic loop 4. ClinVar Uncertain significance, AlphaMissense 0.713, DynaMut2 ΔΔG -1.03 kcal/mol (destabilising).

Identity

Field	Value
Variant	A519V (p.Alanine519Valine)
DNA change	c.1556C>T
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV000166592
Amino acid change	Alanine (A) → Valine (V)

Structural Context

Field	Value
AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 519	85.12 — well-folded
Domain	Cytoplasmic loop 4
Position context	Loop region · position 519 sits between transmembrane segments, solvent-accessible
IDR flag	No — pLDDT above 50 threshold

UniProt features at this position:

(none catalogued)

Position 519 sits in a connecting loop between transmembrane helices. Loop residues are typically solvent-exposed and often contribute to interhelical contacts or serve as recognition sites for binding partners. The wild-type residue is small/hydrophobic (alanine — methyl sidechain); the mutant is small hydrophobic (valine — branched). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.

Computational Predictions

AlphaMissense

Field	Value
am_pathogenicity	0.7125
am_class	likely pathogenic
Interpretation	Likely pathogenic (threshold 0.564)

DynaMut2

Field	Value
ΔΔG (kcal/mol)	-1.03 (Destabilising)
Job ID	178092153173
Result URL	https://biosig.lab.uq.edu.au/dynamut2/results_prediction/178092153173

Clinical Evidence

Field	Value
Classification	Uncertain significance
Review status	criteria provided, multiple submitters, no conflicts
Last evaluated	2025/06/22 00:00
Inheritance	Autosomal dominant pattern indicated by associated DFNA6/14/38 (WFS1 hearing loss 6).
WFS1 variant landscape	A519V is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 catalogued in ClinVar)

Autosomal dominant nonsyndromic hearing loss 6
Type 2 diabetes mellitus
Wolfram syndrome 1
Cataract 41
Wolfram-like syndrome

Research Path Decision Tree

ΔΔG < 2  + binding site affected   →  CATEGORY 3 — docking experiments
ΔΔG 2–4                            →  CATEGORY 2 — pharmacological chaperones
ΔΔG > 4                            →  CATEGORY 1 — gene therapy
pLDDT < 50                         →  CATEGORY 5 — IDR, experimental only
Stable fold + functional site hit  →  CATEGORY 4 — site-specific docking

Final Schema Categorization

Category 3/4 — Most Druggable

<strong>Category 3/4 — Most Druggable</strong><br/><br/>|ΔΔG|=1.03 < 2 kcal/mol (fold intact) + AlphaMissense 0.713 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Why this card matters. Wolframin's fold survives this substitution (|ΔΔG|=1.03 kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.713. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.

Files in this folder

AF-O76024-F1-model_v6.pdb — AlphaFold structure
A519V_molstar_viewer.html — interactive 3D viewer (auto-highlights position 519 with ball-and-stick + neighbors within 5Å)
A519V_variant_card.md — this card (source of truth)
A519V_variant_card.html — styled printable card
A519V_dynamut2_summary.html — clean offline DynaMut2 result card
dynamut2_result.json — structured result data
dynamut2_result_page.html — local snapshot of the Biosig result page (asset URLs absolutized)
A519V_wildtype_interactions.pse / A519V_mutant_interactions.pse — PyMOL sessions

Generated by wolfram-variant-card skill · RareResearch.AI Molecular Atlas Every assumption documented. Every score sourced.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the A519V PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download A519V PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.